Long-term Brodalumab Treatment for axSpA Supported by Phase 3 Data
Long-term treatment with under-the-skin injections of brodalumab safely and effectively reduced disease activity in people with axial spondyloarthritis (axSpA), according to final data from a Phase 3 trial. axSpA is a type of chronic inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is…